source
- Candel Therapeutics shares 20-month follow-up data for its prostate cancer candidate ahead of FDA filingCandel Therapeutics announced that it has completed a long-term follow‑up study of patients treated with its prostate cancer drug. The data extend to about 20 months after treatment and are intende…
- FDA Commissioner Marty Makary Resigns After Turbulent TenureMarty Makary stepped down as commissioner of the U.S. Food and Drug Administration on Tuesday, ending a period marked by controversy and intense scrutiny. His resignation follows a series of publi…